Class-action accuses Takeda of ‘pay-for-delay’ deal with Par
01-07-2021
Takeda ‘to sell OTC business in Europe’ to fund Shire acquisition
31-10-2018
timarbaev / iStockphoto.com
Japan-based Takeda Pharmaceutical has persuaded the European Union Intellectual Property Office (EUIPO) that an applied-for trademark would be confused with its own earlier-registered mark.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Takeda Pharmaceutical, Nikken International, Kenzen, European Union Intellectual Property Office, trademark opposition, cardiovascular
